Zevra Therapeutics IncZVRA
Price$10.97Intrinsic value$7.9028% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $136.1M+476.3% YoYTTM through 30 Jun 2026
Net Income $58.3MTTM through 30 Jun 2026
Free Cash Flow $32.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin94.8%
EBITDA Margin61.6%
Operating Margin143.9%
Net Margin42.8%

Returns

76.7%ROE
41.7%ROA
80.6%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio4.89x
Net Debt-$236.8Mnet cash position
Cash & Equivalents$145.3M

Quality Metrics

Altman Z-Score5.27
Piotroski F-Score5 / 9
FCF Margin24.0%
Rule of 4035.8
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $106.5M
Diluted EPS$0.93TTM
'20'21'24'25
FY2025: $1.45

Dividend

No dividend

Capital Allocation

Capex Intensity0.6%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.